Zhang Qiang, Peng Youyi, Wang Xin I, Keenan Susan M, Arora Sonia, Welsh William J
Department of Pharmacology, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, and Informatics Institute of the University of Medicine & Dentistry of New Jersey, Piscataway, New Jersey 08854, USA.
J Med Chem. 2007 Feb 22;50(4):749-54. doi: 10.1021/jm061142s. Epub 2007 Jan 24.
We describe the synthesis and biological evaluation of a series of tubulin polymerization inhibitors that contain the 1,2,4-triazole ring to retain the bioactive configuration afforded by the cis double bond in combretastatin A-4 (CA-4). Several of the subject compounds exhibited potent tubulin polymerization inhibitory activity as well as cytotoxicity against a variety of cancer cells including multi-drug-resistant (MDR) cancer cell lines. Attachment of the N-methyl-5-indolyl moiety to the 1,2,4-triazole core, as exemplified by compound 7, conferred optimal properties among this series. Computer docking and molecular simulations of 7 inside the colchicine binding site of tubulin enabled identification of residues most likely to interact strongly with these inhibitors and explain their potent anti-tubulin activity and cytotoxicity. It is hoped that results presented here will stimulate further examination of these substituted 1,2,4-triazoles as potential anti-cancer therapeutic agents.
我们描述了一系列含有1,2,4-三唑环的微管蛋白聚合抑制剂的合成及生物学评价,以保留在康普瑞汀A-4(CA-4)中顺式双键所赋予的生物活性构型。其中几种受试化合物表现出强大的微管蛋白聚合抑制活性以及对多种癌细胞(包括多药耐药(MDR)癌细胞系)的细胞毒性。以化合物7为例,将N-甲基-5-吲哚基部分连接到1,2,4-三唑核心上,赋予了该系列化合物最佳性能。对化合物7在微管蛋白的秋水仙碱结合位点内进行计算机对接和分子模拟,能够确定最有可能与这些抑制剂强烈相互作用的残基,并解释它们强大的抗微管蛋白活性和细胞毒性。希望本文给出的结果能够激发对这些取代的1,2,4-三唑作为潜在抗癌治疗药物的进一步研究。